The generic drug approval process has evolved over the past 30 years. In 1970 FDA established the Abbreviated New Drug Application (ANDA) as a mechanism for the review and approval of generic versions of drug products that had been approved between 1938 and 1962. For drugs approved after 1962, manufacturers of generic products were required to submit complete safety and efficacy data. Until 1978 manufacturers conducted clinical efficacy and safety trials. After 1978, however, manufacturers were required to cite published reports of such trials documenting safety and efficacy. Neither of these approaches was considered satisfactory, as the former was quite expensive and the latter required evidence that was usually unavailable, i.e., data that had not been published. In 1984 the Drug Price Competition and Patent Term Restoration Act focused on modifying and accelerating the ANDA procedure and gave FDA statutory authority to approve generic versions of innovator products approved after 1962 as safe and effective.

Unlike the New Drug Application (NDA) process, by which new chemical entities are approved for marketing, the ANDA process as revised in 1984 does not require manufacturers to include preclinical or clinical data establishing the active ingredient’s safety and efficacy[8] because these data were previously documented during the approval process for the innovator product. Because the generic product must be pharmaceutically equivalent and bioequivalent to the innovator product, it is expected that the two products will also be therapeutically equivalent. In other words, the assumption is that if the active ingredient has been shown to be safe and effective after it is absorbed into the bloodstream, any product that gives rise to the same concentrations of active ingredient in the body to the same rate and extent will produce the same effect; therefore, preclinical and clinical studies of the generic product are usually deemed unnecessary. FDA classifies products as therapeutically equivalent if they:

• Have been shown to be safe and effective.
• Are bioequivalent in that there is no known or potential bioequivalence problem and the products meet acceptable in vitro standards or, if the products do present a potential or demonstrated bioequivalence problem, they meet appropriate bioequivalence requirements.
• Have similar potential for safety and efficacy.
• Are appropriately labeled.
• Are manufactured in compliance with Current Good Manufacturing Practice guidelines.

An Abbreviated New Drug Application (ANDA) is an application for a US generic drug approval for an existing licensed medication or approved drug.

The ANDA contains data which when submitted to FDA’s Center for Drug Evaluation and Research, Office of Generic Drugs, provides for the review and ultimate approval of a generic drug product. Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, low cost alternative to the American public.

A generic drug product is one that is comparable to an innovator drug product in dosage form, strength, route of administration, quality, performance characteristics and intended use. All approved products, both innovator and generic, are listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).

Generic drug applications are termed “abbreviated” because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent (i.e., performs in the same manner as the innovator drug). One way scientists demonstrate bioequivalence is to measure the time it takes the generic drug to reach the bloodstream in 24 to 36 healthy volunteers. This gives them the rate of absorption, or bioavailability, of the generic drug, which they can then compare to that of the innovator drug. The generic version must deliver the same amount of active ingredients into a patient’s bloodstream in the same amount of time as the innovator drug.

Using bioequivalence as the basis for approving generic copies of drug products was established by the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act. This Act expedites the availability of less costly generic drugs by permitting FDA to approve applications to market generic versions of brand-name drugs without conducting costly and duplicative clinical trials. At the same time, the brand-name companies can apply for up to five additional years longer patent protection for the new medicines they developed to make up for time lost while their products were going through FDA’s approval process. Brand-name drugs are subject to the same bioequivalence tests as generics upon reformulation.

Drug stores are aware of the concerns of the medical establishment as to fact that not everyone who uses the trio of erectile dysfunction drugs (Viagra,Cialis,Levitra)actually is suffering from a serious erection problem but they may just be requiring a boost in the bedroom department. The problem is not helped by the fact that Viagra is a household name now and that men no longer have a reason for not being able to perform all the time and the pressure on men to perform is greater than it ever was. The sexual liberation of many women has meant that they demand much more from their men these days.

The advertising of the erectile dysfunction drugs has meant that men are increasingly looking to the drugs to boost their performance in bed and it is the women who get the most benefits from the drugs as their men are able to last longer and have harder erections. The makers of Viagra, Cialis and Levitra all say that they aim their advertising and promotion at men with real erection problems but the definition of an erection problem is difficult to define and difficult to prove to a doctor who examines you.

If you go to a docor and say you have an erection problem and you tell him you are healthy and well and have no blood pressure problems it is almost impossible for him to refuse you treatment with either Viagra, Levitra or Cialis. However this doesn’t mean that the drug is always abused as it has been known to save many a flagging marriage and give new impetus and intimacy to a relationship that is dying. Ukmedix takes great pride in the fact that it has helped thousands of couples who have sexual problems and who have a difficulty facing a doctor face to face with the problem, something that can be very humiliating and distressing for both parties in a sexual relationship.